Status: Not yet recruiting
Adhesion and Safety of Rotigexole Compared to Neupro®
A non-inferiority open-labelled crossover randomized controlled trial, of two arms, to investigate the adhesiveness and safety of Rotigexole 8 mg/24 hours transdermal patch, manufactured by Eva pharma, Egypt, compared to the innovator product, Neupro® 8 mg/ 24 hours transdermal patch, manufactured by UCB Pharma S.A., Belgium, after 24 hours of application
Participants needed: 40
Trial details
Age: 30+Biological sex: AllType: InterventionalSponsor: Eva PharmaUpdated: Aug 7, 2025
Eligibility criteria
Male or Female patients aged ≥30 years at Screening [+8]
Patients with a medical history indicating a Parkinsonian syndrome other than id... [+17]